JP2011522864A5 - - Google Patents

Download PDF

Info

Publication number
JP2011522864A5
JP2011522864A5 JP2011512988A JP2011512988A JP2011522864A5 JP 2011522864 A5 JP2011522864 A5 JP 2011522864A5 JP 2011512988 A JP2011512988 A JP 2011512988A JP 2011512988 A JP2011512988 A JP 2011512988A JP 2011522864 A5 JP2011522864 A5 JP 2011522864A5
Authority
JP
Japan
Prior art keywords
use according
seq
medicament
amino acid
cac
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011512988A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011522864A (ja
JP5481473B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2009/057263 external-priority patent/WO2009150214A2/en
Publication of JP2011522864A publication Critical patent/JP2011522864A/ja
Publication of JP2011522864A5 publication Critical patent/JP2011522864A5/ja
Application granted granted Critical
Publication of JP5481473B2 publication Critical patent/JP5481473B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011512988A 2008-06-13 2009-06-12 糖尿病患者における血管リモデリングおよび心血管疾患治療のための治療薬としての非アシル化グレリンおよび類似体 Expired - Fee Related JP5481473B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6116308P 2008-06-13 2008-06-13
US61/061,163 2008-06-13
PCT/EP2009/057263 WO2009150214A2 (en) 2008-06-13 2009-06-12 Unacylated ghrelin and analogs as therapeutic agents for vascular remodeling in diabetic patients and treatment of cardiovascular disease

Publications (3)

Publication Number Publication Date
JP2011522864A JP2011522864A (ja) 2011-08-04
JP2011522864A5 true JP2011522864A5 (https=) 2012-07-05
JP5481473B2 JP5481473B2 (ja) 2014-04-23

Family

ID=41078180

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011512988A Expired - Fee Related JP5481473B2 (ja) 2008-06-13 2009-06-12 糖尿病患者における血管リモデリングおよび心血管疾患治療のための治療薬としての非アシル化グレリンおよび類似体

Country Status (8)

Country Link
US (2) US8476408B2 (https=)
EP (1) EP2310041B1 (https=)
JP (1) JP5481473B2 (https=)
CN (1) CN102065883A (https=)
AU (1) AU2009256558B2 (https=)
CA (1) CA2723270C (https=)
MX (1) MX2010013677A (https=)
WO (1) WO2009150214A2 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9651708B2 (en) * 2011-04-21 2017-05-16 Baker Hughes Incorporated Method of mapping reservoir fluid movement using gravity sensors
PL2790721T3 (pl) 2011-12-15 2019-05-31 Millendo Therapeutics Sas Fragmenty nieacylowanej greliny do zastosowania do leczenia zespołu pradera-williego
US10016458B2 (en) 2012-04-16 2018-07-10 Baystate Health, Inc. p53 silenced endothelial progenitor cells for diabetes
WO2013190520A2 (en) 2012-06-22 2013-12-27 The General Hospital Corporation Gh-releasing agents in the treatment of vascular stenosis and associated conditions
EP3010529B1 (en) 2013-06-21 2020-05-06 Millendo Therapeutics SAS Use of unacylated ghrelin, fragments and analogs thereof as antioxidant
WO2015168207A1 (en) * 2014-04-29 2015-11-05 Mayo Foundation For Medical Education And Research Butyrylcholinesterases having an enhanced ability to hydrolyze acyl ghrelin
WO2018053216A1 (en) 2016-09-15 2018-03-22 Mayo Foundation For Medical Education And Research Methods and materials for using butyrylcholinesterases to treat cancer
GB201918853D0 (en) * 2019-12-19 2020-02-05 Lund Lars H Methods of treatment

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5643872A (en) * 1989-10-23 1997-07-01 Smithkline Beecham Corporation Cyclic anti-aggregatory peptides
US5747296A (en) * 1992-05-11 1998-05-05 Corvas International, Inc. Method of detecting neutophil inhibitory factor mimics
WO1994013692A1 (en) * 1992-12-10 1994-06-23 Regents Of The University Of Minnesota Polypeptides useful for treating inflammatory disorders
US5786332A (en) * 1995-03-06 1998-07-28 Trega Biosciences, Inc. Cytokine restraining agents and methods of use in pathologies and conditions associated with altered cytokine levels
WO1995014787A1 (en) * 1993-11-22 1995-06-01 Centocor, Inc. Peptide inhibitors of selecting binding
US5695761A (en) * 1993-12-23 1997-12-09 Rutgers University Suppression of nitric oxide production by osteopontin
KR100360639B1 (ko) * 1994-03-09 2003-01-30 코르텍, 인크. N-치환글리신함유브라디키닌길항제펩티드
US5958875A (en) * 1996-03-29 1999-09-28 The Regents Of The University Of California Synthetic peptides derivatives with nerve growth factor-like neurotrophic activity
US6627729B1 (en) * 1997-03-24 2003-09-30 Zymogenetics, Inc. TML peptides
US5932548A (en) * 1998-06-03 1999-08-03 Deghenghi; Romano Lysine containing peptides for treatment of heart disease
WO2000023469A2 (en) * 1998-10-16 2000-04-27 Musc Foundation For Research Development Fragments of insulin-like growth factor binding protein and insulin-like growth factor, and uses thereof
WO2001056592A1 (en) 2000-02-01 2001-08-09 Novo Nordisk A/S Use of compounds for the regulation of food intake
EP1286697A2 (en) 2000-05-17 2003-03-05 Eli Lilly And Company Method for selectively inhibiting ghrelin action
US6967237B2 (en) * 2000-05-30 2005-11-22 Merck & Co., Inc. Ghrelin analogs
JP4493913B2 (ja) 2001-01-31 2010-06-30 中外製薬株式会社 低栄養症状疾患治療剤
US6872548B2 (en) * 2001-01-31 2005-03-29 Human Genome Sciences, Inc. Scaffolded fusion polypeptides and compositions and methods for making the same
CA2470235C (en) 2001-12-18 2012-02-07 Theratechnologies Inc. Pharmaceutical compositions comprising unacylated ghrelin and therapeutical uses thereof
US7666833B2 (en) * 2001-12-18 2010-02-23 Alizé Pharma SAS Pharmaceutical compositions comprising unacylated ghrelin and therapeutical uses thereof
AU2002351593A1 (en) * 2001-12-18 2003-06-30 Theratechnologies Inc. Pharmaceutical compositions comprising unacylated ghrelin and therapeutical uses thereof
AU2002364586A1 (en) * 2001-12-21 2003-07-30 Delta Biotechnology Limited Albumin fusion proteins
EP1506786B1 (en) 2002-05-21 2016-11-23 Daiichi Sankyo Company, Limited Medicinal compositions containing ghrelin
AU2004249904A1 (en) * 2003-06-18 2004-12-29 Direvo Biotech Ag New biological entities and the pharmaceutical or diagnostic use thereof
US7517269B2 (en) 2003-08-12 2009-04-14 Parvia Corp. Building element for constructing a modular substructure
US7825090B2 (en) 2003-10-24 2010-11-02 Alizé Pharma SAS Use of ghrelin and unacylated ghrelin compositions for treating insulin resistance
US8076288B2 (en) * 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
US20070237775A1 (en) * 2004-07-14 2007-10-11 Eli Lilly And Company Anti-Ghrelin Antibodies
WO2006045319A2 (en) 2004-10-27 2006-05-04 Gastrotech Pharma A/S Uses of growth hormone secretagogues in the treatment of individuals suffering from renal and/or liver failure
CA2587627A1 (en) * 2004-11-15 2006-05-26 Eli Lilly And Company Desacyl ghrelin antibodies and therapeutic uses thereof
WO2007126792A2 (en) 2006-03-28 2007-11-08 Liat Mintz Use of ghrelin splice variant for treating high cholesterol levels or high plasma glucose levels and releated diseases
EP2152297B1 (en) * 2007-05-31 2015-04-29 Alizé Pharma SAS Unacylated ghrelin as therapeutic agent in the treatment of metabolic disorders
EP2067481A1 (en) 2007-12-03 2009-06-10 Charité-Universitätsmedizin Berlin Therapeutic use of desacyl ghrelin

Similar Documents

Publication Publication Date Title
JP2011522864A5 (https=)
ES2875748T3 (es) Nuevos derivados de oxintomodulina y composición farmacéutica para el tratamiento de la obesidad que los comprende
JP2010031018A5 (https=)
JP2014501762A5 (https=)
ME02662B (me) Niskofrekventna terapija glatiramer acetatom
JP2013515009A5 (https=)
JP2012041342A5 (https=)
JP2016516016A5 (https=)
FI3356386T3 (fi) Melanokortiini-4-reseptoripolkuun liittyvien häiriöiden hoitamismenetelmä
JP2011105728A5 (https=)
JP2011528333A5 (https=)
JP2020062028A5 (https=)
RU2013139651A (ru) Новые соединения, влияющие на пищевое поведение
JP2013510169A5 (https=)
JP2014532722A5 (https=)
JP2016512205A5 (https=)
JP2014506579A5 (https=)
JP2006518750A5 (https=)
Chen et al. Intermittent fasting in type 2 diabetes: from fundamental science to clinical applications.
WO2009150214A3 (en) Unacylated ghrelin and analogs as therapeutic agents for vascular remodeling in diabetic patients and treatment of cardiovascular disease
RU2007143510A (ru) Инсулиновые композиции
EP4126961A1 (en) Anti-cd6 antibody compositions and methods for treating and reducing negative effects of a coronavirus including covid-19
WO2025195268A1 (zh) 药物组合物在治疗糖尿病周围神经病变上的应用
WO2007029041A2 (en) Interferon lambda therapy for treatment of respiratory diseases
US20230210942A1 (en) Methods and compositions for modulating endothelial cell dysfunction